336 research outputs found
Bonfini Héródianosz-fordításáról
No full textBefore entering Matthias’ service, Antonio Bonfini dedicated to the king, among his other literary products, his freshly made translation of Herodian as well. The manuscript presented, which was partly copied by the author himself, is now kept in Salzburg (UB M II. 135). The text, however, is preserved in another copy (Vat. Ross. 483), neglected by most specialists of the field. This paper has a threefold aim. First, it examines the textual relationship of the two versions. Second, it analyizes the value of Bonfini’s – now lost – Greek original, as it can be extrapolated on the basis of the Latin translation, in constituting Herodian’s text, whether it contained readings not preserved in other manuscripts. Third, it compares Bonfini’s translation to that of Poliziano, which was made roughly at the same time or slightly later, but independently of his much less known colleague’s version
Randomized trial of sequential administration of G-CSF and GM-CSF versus G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
No full textA trial was conducted to investigate whether the sequential administration of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) could accelerate reconstitution of hematopoiesis, compared with G-CSF alone following high-dose chemotherapy (HDCT). A group of 34 consecutive patients with solid tumors undergoing HDCT and autologous peripheral blood progenitor cell (PBPC) transplantation was studied. Conditioning regimen included carboplatin, etoposide, mitoxantrone, and melphalan for breast cancer and cyclophosphamide or ifosfamide, carboplatin, and etoposide for the other tumors, HDCT was delivered from day -3 to day -1, PBPC were infused on day 0, and on the same day growth factors were administered subcutaneously (s.c.)5 mu g/kg each. Seventeen patients were randomized to receive G-CSF from day 0 to day 13 after HDCT (arm A), and 17 patients received G-CSF from day 0 to day 6 and GM-CSF from day 7 to day 13 (arm B). Patients were stratified, and their characteristics were homogeneous in both arms for age, performance status, and number of previous chemotherapy courses and CD34(+) infused. The median time to absolute neutrophil count (ANC) >500/mu l was 10 days in arm A and 9 days in arm B (p = 0.96). Days to platelet (PLT) count > 20,000 were not different in the two treatment arms (p = 0.1), but patients randomized to arm A had a lower platelet count compared with patients in arm B, One month after PBPC transplantation, a statistically significant difference in PLT count was observed (arm A median 150 x 10(3)/mu l (90-310), arm B median 254 x 10(3)/mu l (117-387), p = 0.13). The days patients had fever >38 degrees C were 39 in arm A and 26 in arm B (p = 0.18). The difference in the length of hospital stay was not statistically significant between the groups (Mann-Whitney sum rank test). After a median follow-up of 30 months, 21 patients were alive and 20 were disease free. These data show that the two growth factors are associated with different patterns of hematopoietic recovery, and larger randomized trials in groups of more homogeneous patients will be needed to define the effects and benefits of combination growth factor therapies
Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells.
No full textGene therapy has been proposed as a definitive
cure for ββ-thalassemia. We applied a gene targeting
approach, based on the introduction of small DNA
fragments (SDF) into erythroid progenitor cells, to
specifically modify the ββ-globin gene sequence at
codon 39. The strategy was first tested in normal
individuals by delivering mutant SDF that were
able to produce the ββ39 (C→→T) mutation. Secondly,
wild-type SDF were electroporated into target cells
of ββ39/ββ39. ββ-thalassemic patients to correct the
endogenous mutation. In both cases, gene modification
was assayed by allele-specific polymerase
chain reaction of DNA and mRNA, by restriction
fragment length polymorphism analysis and by
direct sequencing
Cross‐reactivity in serological tests for brucellosis: A comparison of immune response of escherichia coli o157:H7 and yersinia enterocolitica o:9 vs brucella spp
No full textAccording to European Union (EU) regulations, the serological tests for the eradication of bovine and ovine brucellosis are the Rose Bengal Test, Complement Fixation Test, and i-ELISA. These methods, also recommended by the World Organization for Animal Health (OIE) for international trades, have limitations related to the use of suspensions of smooth Brucellae or LPS extracts. Limitations include false-positive serological reactions to brucellosis, which in turn impedes accurate diagnosis in some herds. False positive reactions should be considered carefully during the final stages of an eradication programme and for surveillance purposes in brucellosis-free areas. In this study, we produced specific sera through the experimental infection of sheep with Y. enterocolitica 0:9 and E. coli 0157:H7. These are the most important cross-reactive bacteria with Brucella. We then evaluated the antibody response of groups of sheep that had been immunised towards homologous antigens and official antigens for brucellosis, in order to identify a differential diagnostic protocol to distinguish cross-reaction in Brucella-infected animals
Complementary taphonomies:Medieval sturgeons from Hungary
No full textThis is a review of the Medieval exploitation of Acipenserids in Hungary. Owing to their generally large size and high value these fish have been central to fishing cultures since Prehistory. The focus of discussion is the contradictory preservation of sturgeon remains (large but mostly porous bones) and the relative overrepresentation of this "Royal fish" in the scarce written record in Hungary. Both sources are reviewed in taphonomic terms and evaluated from an ichtyological point of view
SARS-CoV-2 Transmission Control Measures in the Emergency Department: The Role of Rapid Antigenic Testing in Asymptomatic Subjects
No full textLimiting transmission of SARS-CoV-2 from asymptomatic people assumes the paramount importance of keeping fragile subjects protected. We evaluated the utility of rapid SARS-CoV-2 antigen testing in asymptomatic subjects attending emergency departments in non-COVID-19 areas, using a single nasopharyngeal swab specimen collected in universal transport medium to perform both rapid antigen testing and rRT-PCR (used as reference standard) in a cohort of 899 patients. In the overall sample, the rapid antigen test had 43.9% sensitivity, 100% specificity, 100% positive predictive value, 93.6% negative predictive value. Considering subjects with rRT-PCR cycle threshold ≤30, the test had 80.4% sensitivity, 100% specificity, 100% positive predictive value, 98.8% negative predictive value. Considering subjects with rRT-PCR cycle threshold ≤25, the test had 94.7% sensitivity, 100% specificity, 100% positive predictive value and 99.7% negative predictive value. Despite low sensitivity, routine application of rapid antigen testing in the emergency department can lead to isolation in less than 30 min of about a half of asymptomatic COVID-19 subjects assigned to non-COVID-19 areas by clinical triage. The rapid test correctly identified 94.7% of asymptomatic patients with cycle threshold ≤ 25 that are supposed to be more infective; thus, it could be a useful measure to contain viral transmission in non-COVID-19 areas
An ultra low power switched opamp-based 10-bit integrated ADC for implantable biomedical applications
No full text- …
